Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicySFHP Clinical Trial Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentSan Francisco Health PlanPolicy CO-47

    Clinical Trials

    Customize your policy alerts

    Sign up for sanfranciscohealthplan Policy CO-47 alerts

    Get alerted when Policy CO-47 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs SFHP member access to qualifying clinical trials for cancer and other serious or life-threatening diseases or conditions, including eligibility, consultations, routine patient care costs, prior authorization, and exclusions. Applies to SFHP Medi-Cal, Care Plus (HMO D-SNP), and Healthy Workers HMO members and providers.

    Policy Summary
    PayerSan Francisco Health Plan
    PolicyClinical Trials
    Policy CodePolicy CO-47
    Change TypeNo material change
    Effective DateJan 1, 2013
    Next Review DateN/A
    Key ActionInclude the qualifying or national clinical trial identifier number with applicable consultation or service authorization requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    72 hoursExpedited prior authorization processing
    NoneAdditional requirements for routine patient care costs
    3 pathwaysQualifying clinical trial pathways
    7 exclusionsExcluded item and service categories

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Out-of-network covered
    Routine care coverage when no network trial is available

    Qualifying Clinical Trial Coverage

    Qualified Enrollee

    A member is a qualified enrollee when all of the following are met:

    Qualified enrollee requirements

    • Protocol eligibility: The member is eligible to participate in an approved clinical trial, according to the clinical trial protocol, for the treatment of cancer or another life-threatening disease or condition.
    • Appropriateness pathway

      • The referring health care professional is an SFHP network provider and has concluded that the member's participation in the clinical trial would be appropriate.
      • The member provides medical and scientific information establishing that participation in the clinical trial would be appropriate.

    Qualifying Clinical Trial

    A clinical trial qualifies when at least one of the following pathways is met. The study may be conducted in any clinical phase and must concern prevention, detection, or treatment of cancer or another life-threatening disease or condition.

    Qualifying clinical trial pathways

    • Approved or funded study: The study or investigation is approved or funded, including through in-kind donations, by one or more specified governmental, cooperative, or qualified nongovernmental entities. These include the National Institutes of Health, CDC, AHRQ, CMS, qualifying cooperative groups or centers, qualified nongovernmental research entities identified in NIH guidelines, or the Department of Veterans Affairs, Department of Defense, or Department of Energy when the required comparable peer-review standards are met.
    • FDA investigational new drug pathway: The study or investigation is conducted under an investigational new drug application reviewed by the United States Food and Drug Administration.
    • FDA-exempt drug trial pathway: The study or investigation is a drug trial that is exempt from an investigational new drug application reviewed by the United States Food and Drug Administration.

    Routine Patient Care Costs

    SFHP covers routine patient care costs for a qualified enrollee participating in a qualifying clinical trial when all of the following apply:

    Routine patient care cost coverage

    • The member is a qualified enrollee participating in a qualifying clinical trial.
    • The item or service is a routine patient care cost that would otherwise be covered under the member's plan or contract if it were not provided in connection with the qualifying clinical trial.

      Routine patient care costs include health care services typically provided absent a clinical trial; services required solely to provide the investigational drug, item, device, or service; clinically appropriate monitoring; and services needed to prevent, diagnose, or treat complications arising from the investigational intervention.

    • Location and network coverage: The routine patient care cost is furnished in connection with the qualifying clinical trial.

      If the qualifying clinical trial is not offered through SFHP's provider network, SFHP covers routine patient care costs regardless of geographic location or whether the treating provider or principal investigator is in network. SFHP may request the trial participation information and identifier to determine trial location and network availability.

    Investigational Services

    Investigational services may be covered when all of the following regulatory requirements are met:

    Investigational service coverage

    • The service is an investigational service as defined in 22 CCR section 51056.1(b).
    • The service is determined to be investigational pursuant to 22 CCR section 51056.1(c).
    • All requirements in 22 CCR section 51303(h) are met.
    • The applicable requirements are documented in the member's medical record.

      Refer to CO-59: Experimental or Investigational Services for additional information regarding investigational services.

    The investigational drug, item, device, or service that is the subject of the qualifying clinical trial is excluded from payment.

    Items and services excluded under the member’s Care Plus, Medi-Cal, or Healthy Workers HMO benefit program remain excluded from coverage.

    Travel, housing, companion expenses, and other nonclinical expenses associated with the clinical trial are excluded when they are not otherwise covered by the member’s benefit program.

    Drugs, items, devices, and services provided only for research, data collection, or analysis are excluded when they are not used in the member’s direct clinical management.

    Drugs, items, devices, and services provided free of charge by the research sponsor are excluded from payment.

    Diagnostic and imaging services provided by out-of-medical-group or out-of-plan providers are excluded unless authorized by SFHP and/or the qualifying clinical trial is not offered or available through an SFHP network provider.

    Authorization and Submission Requirements

    Prior Authorization

    Prior Authorization for Out-of-Network Consultations

    Consultations by an SFHP network provider within the member’s medical group or network do not require prior authorization. A consultation performed outside the member’s medical group or network requires prior authorization submitted to SFHP’s Prior Authorization team.

    • Include the qualified clinical trial identifier number with the request.
    Prior Authorization

    Routine Service Authorization Still Applies

    Covered services associated with a qualifying clinical trial do not receive different or additional authorization requirements. However, any covered routine service that ordinarily requires prior authorization remains subject to that requirement, whether or not it is related to a qualifying clinical trial.

    • SFHP’s Prior Authorization team processes requests under the expedited process, generally within 72 hours.
    • Use SFHP’s Prior Authorization Service Code Lookup Tool at www.sfhp.org to verify CPT and HCPCS authorization requirements.

    Policy Scope and Purpose

    San Francisco Health Plan (SFHP) provides qualified enrollees access to qualifying clinical trials for cancer and other serious or life-threatening diseases or conditions. The policy addresses coverage of eligible routine patient care costs associated with these trials while identifying services and expenses that are excluded from payment.

    Key Terms

    Life-Threatening Disease or Condition
    DefinitionA disease or condition from which the likelihood of death is probable.
    Required conditionThe course of the disease or condition must be interrupted to prevent the probable likelihood of death.
    Policy scopeIncludes cancer and other life-threatening diseases or conditions addressed by a qualifying clinical trial.
    Qualified Enrollee
    Protocol eligibilityThe member is eligible to participate in an approved clinical trial, according to the clinical trial protocol, for treatment of cancer or another life-threatening disease or condition.
    SFHP network provider pathwayThe referring health care professional is an SFHP network provider and has concluded that the member's participation in the clinical trial would be appropriate because the member meets the protocol eligibility condition.
    Policy Summary
    PayerSan Francisco Health Plan
    PolicyClinical Trials
    Policy CodePolicy CO-47
    Change TypeNo material change
    Effective DateJan 1, 2013
    Next Review DateN/A
    Key ActionInclude the qualifying or national clinical trial identifier number with applicable consultation or service authorization requests.
    SourceLink
    On This Page
    Qualifying Clinical Trial CoverageAuthorization and Submission RequirementsPolicy Scope and PurposeKey Terms
  1. Authorization treatment: Any covered service that routinely requires prior authorization continues to require prior authorization when furnished in connection with the qualifying clinical trial.

    SFHP does not impose different or additional prior authorization requirements because the service is related to a qualifying clinical trial. SFHP processes applicable requests through its expedited process within 72 hours. Out-of-medical-group or out-of-plan providers must submit authorization requests for services requiring authorization on the member's behalf.

  2. Documentation Required

    Medi-Cal Trial Approval Documentation

    For the Medi-Cal line of business, approval of a qualifying clinical trial requires submission of the Medicaid Attestation Form on the Appropriateness of the Qualifying Clinical Trial.

    • The form must include the member’s name and client identification number.
    • Include the national clinical trial number.
    • Include a statement signed by the principal investigator attesting to the appropriateness of the qualifying clinical trial.
    • Include a statement signed by the provider attesting to the appropriateness of the qualifying clinical trial.
    Prior Authorization

    OOMG and OOP Authorization Submission

    Most covered services rendered by an out-of-medical-group (OOMG) or out-of-plan (OOP) provider require prior authorization, whether or not they are related to a qualifying clinical trial. The OOMG or OOP provider must submit the authorization request to SFHP’s Outpatient team on the member’s behalf.

    • SFHP’s Outpatient team may request information about the member’s participation and the qualified clinical trial identifier to determine the trial’s location and whether an SFHP network trial is available.
    Documentation Required

    Medi-Cal Clinical Trial Attestation

    Medi-Cal providers submitting a qualifying clinical trial approval request must submit the Medicaid Attestation Form on the Appropriateness of the Qualifying Clinical Trial with complete member, provider, and trial documentation.

    • Member: name and client identification number.
    • Trial: national clinical trial number.
    • Principal investigator: signed statement attesting to the appropriateness of the qualifying clinical trial.
    • Provider: signed statement attesting to the appropriateness of the qualifying clinical trial.
    Documentation Required

    Clinical Trial Identifier Required

    Authorization and consultation requests must identify the applicable qualifying clinical trial. SFHP may require the identifier to evaluate eligibility, process authorization, and determine whether the trial is available through the SFHP network.

    • Include the qualified clinical trial identifier number for out-of-network eligibility consultations.
    • Include the national clinical trial number on the Medi-Cal Medicaid Attestation Form.
    • Provide the qualified clinical trial identifier number when requested by SFHP’s Outpatient team.
    Denial Risk

    Excluded Trial-Related Services

    SFHP will not pay for investigational items or services that are the subject of the qualifying clinical trial, excluded benefits, research-only services, or nonclinical expenses. Claims may also be denied when the participant receives the drug, item, device, or service free from the trial sponsor.

    • Excluded or nonclinical expenses include travel, housing, and companion expenses unless otherwise covered by the member’s benefit program.
    • Research activities, data collection, and analysis are excluded when not used in the member’s direct clinical management.
    • Diagnostic and imaging services from an OOMG or OOP provider are excluded unless authorized by SFHP or the clinical trial is not offered or available through an SFHP network provider.
    Prior Authorization

    Ordinary Authorization Requirements Still Apply

    Associated covered services remain subject to their ordinary prior authorization requirements at the CPT and HCPCS code level. A qualifying clinical trial does not waive authorization rules for services that routinely require authorization.

    • Authorization requirements for new CPT and HCPCS codes are reviewed through DHCS standing monthly code loads.
    • Cancer biomarker tests associated with a federal FDA-approved therapy for advanced or metastatic stage 3 or 4 cancer are configured to never require prior authorization under DHCS APL 22-010 and Health and Safety Code §1370.6.
    Member evidence pathwayThe member provides medical and scientific information establishing that participation in the clinical trial would be appropriate because the member meets the protocol eligibility condition.
    Qualifying Clinical Trial
    ScopeA clinical trial in any clinical phase conducted in relation to the prevention, detection, or treatment of cancer or another life-threatening disease or condition.
    Approved or funded studyThe study or investigation is approved or funded, which may include funding through in-kind donations, by one or more specified governmental, cooperative, or qualified nongovernmental entities, including the National Institutes of Health, CDC, AHRQ, CMS, qualifying cooperative groups or centers, qualified nongovernmental research entities, or the Departments of Veterans Affairs, Defense, or Energy through the specified peer-review process.
    FDA investigational new drug pathwayThe study or investigation is conducted under an investigational new drug application reviewed by the United States Food and Drug Administration.
    FDA-exempt drug trial pathwayThe study or investigation is a drug trial that is exempt from an investigational new drug application reviewed by the United States Food and Drug Administration.
    Routine Patient Care Costs
    DefinitionCosts associated with providing health care services, including drugs, items, devices, and services that would otherwise be covered under the plan or contract if they were not provided in connection with a qualifying clinical trial program.
    Usual careHealth care services typically provided absent a clinical trial.
    Provision and monitoringHealth care services required solely for the provision of the investigational drug, item, device, or service, or for clinically appropriate monitoring of the investigational item or service.
    Complication prevention and treatmentHealth care services provided for the prevention of complications arising from the investigational drug, item, device, or service, including diagnosis or treatment of the complications.
    Reasonable and necessary careHealth care services needed for the reasonable and necessary care arising from the provision of the investigational drug, item, device, or service, including diagnosis and treatment of complications.